The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen, Inc. is advancing one-time gene therapies designed to address hundreds of genetic mutations responsible for vision loss, with ambitions to tackle the 132 billion dollar annual global burden associated with the condition.
In a recent interview with PharmaVoice, Ocugen, Inc. CEO Dr. Shankar Musunuri described gene therapy as a transformative innovation likely to be considered one of the greatest discoveries of the 21st century. The company’s research underscores the growing interest among biotech firms in pioneering treatments for genetic disorders, signaling the ongoing evolution of vision care.
Ocugen has accelerated development of modifier gene therapies targeting major blindness diseases, according to a previous report on innovation in the sector. The company has also recognized women leaders driving gene therapy advancement, marking International Women’s Day with an industry spotlight on female innovators. These efforts highlight the firm's continued focus on research and talent in genetic vision loss treatment.